CVE:HTLHamilton Thorne Stock Price, Forecast & News

C$1.37

+0.03 (+2.24 %)

(As of 08/4/2020 04:00 PM ET)

Add

Compare

Today's Range

C$1.34

Now: C$1.37▼

C$1.37

50-Day Range

C$1.11

MA: C$1.21▼

C$1.34

52-Week Range

C$0.86

Now: C$1.37▼

C$1.50

Volume13,810 shs

Average Volume192,726 shs

Market CapitalizationC$189.32 million

P/E Ratio114.17

Dividend YieldN/A

BetaN/A

Hamilton Thorne Ltd., together with its subsidiary, Hamilton Thorne, Inc., develops, manufactures, and sells precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell, and developmental biology research markets. The company offers clinical lasers, such as LYKOS and ZILOS-tk lasers, as well as clinical laser software and hardware for clinical assisted reproduction; and research lasers, including XYRCOS and XYClone lasers for stem cell research, gene targeting, knock out mouse production, SCNT, ICSI, IVF, and assisted hatching applications, as well as Stiletto lasers for isolation of cells of interest, ablation of unwanted cells, and precision scoring of cell colonies. It also provides clinical sperm analysis (CASA) products comprising IVOS II Clinical and CEROS II Clinical, as well as Human Motility II and Dimensions II Strict Morphology software to clinics, hospitals, and assisted reproduction centers; animal and research CASA systems, and motility software packages; and various sperm analyzer options. In addition, the company offers sperm analysis accessories, such as accu-beads+ for use in counting procedures in semen analysis; 2X-CEL disposable semen analysis slides; IDENT Stains for determining sperm motility and concentration; VIADENT stain to determine viable sperm count, concentration, and percentage from a motile sample; and MiniTherm Stage Warmer for CASA and manual sperm motility analysis. Further, it offers IMSI-Strict, an automated software solution for live sperm morphology under high magnification; Oosight imaging system for research purposes; and CIVA, a custom software to capture images/video and annotate. The company sells its products to pharmaceutical and biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Hamilton Thorne Ltd. is based in Beverly, Massachusetts.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Hamilton Thorne has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$1.63, Hamilton Thorne has a potential upside of 20.4% from its current price of C$1.35.
Amount of Analyst Coverage
Hamilton Thorne has only been the subject of 2 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Hamilton Thorne has received 73 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hamilton Thorne has received 53 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hamilton Thorne has received 57.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hamilton Thorne and other stocks. Vote “Outperform” if you believe HTL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HTL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Hamilton Thorne does not currently pay a dividend.
Dividend Growth
Hamilton Thorne does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hamilton Thorne insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$177,895.00 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hamilton Thorne is 112.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.86.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hamilton Thorne is 112.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.48.
Price to Book Value per Share Ratio
Hamilton Thorne has a P/B Ratio of 4.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.08 out of 5 stars

Industry, Sector and Symbol

Stock Exchange CVE

Industry Medical Devices

Sub-IndustryN/A

SectorMedical

Current SymbolCVE:HTL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.hamiltonthorne.com

Phone+1-978-9212050

Debt

Debt-to-Equity Ratio39.38

Current Ratio2.25

Quick Ratio1.59

Price-To-Earnings

Trailing P/E Ratio114.17

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesC$38.12 million

Price / Sales4.97

Cash FlowC$0.13 per share

Price / Cash Flow10.33

Book ValueC$0.30 per share

Price / Book4.61

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares138,193,000

Market CapC$189.32 million

Next Earnings Date8/25/2020 (Estimated)

OptionableNot Optionable

C$1.37

+0.03 (+2.24 %)

(As of 08/4/2020 04:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive HTL News and Ratings via Email

Sign-up to receive the latest news and ratings for HTL and its competitors with MarketBeat's FREE daily newsletter.

Hamilton Thorne (CVE:HTL) Frequently Asked Questions

How has Hamilton Thorne's stock been impacted by COVID-19 (Coronavirus)?

Hamilton Thorne's stock was trading at C$1.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HTL shares have increased by 13.2% and is now trading at C$1.37.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hamilton Thorne?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hamilton Thorne in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Hamilton Thorne.

When is Hamilton Thorne's next earnings date?

Hamilton Thorne is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020.
View our earnings forecast for Hamilton Thorne.

What price target have analysts set for HTL?

2 brokers have issued twelve-month price objectives for Hamilton Thorne's shares. Their forecasts range from C$1.45 to C$1.80. On average, they anticipate Hamilton Thorne's share price to reach C$1.63 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price.
View analysts' price targets for Hamilton Thorne.

Has Hamilton Thorne been receiving favorable news coverage?

News headlines about HTL stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hamilton Thorne earned a news sentiment score of -3.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the near future.
View the latest news about Hamilton Thorne.

Who are some of Hamilton Thorne's key competitors?

Some companies that are related to Hamilton Thorne include Zynex (ZYXI), Neuronetics (VMD), Avacta Group (AVCT), Creo Medical Group (CREO), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Titan Medical (TMD), Somnomed (SOM), Resonance Health (RHT), Advanced Oncotherapy (AVO) and REVA Medical (RVA).
View all competitors.

What other stocks do shareholders of Hamilton Thorne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hamilton Thorne investors own include Trican Well Service (TCW), Mediagrif Interactive Technologies (MDF), Micron Technology (MU), LHC Group (LHCG), Mainstreet Equity (MEQ), Materialise (MTLS), WPT Industrial Real Estate Investment (WIR.U), WPT Industrial REIT (WIR.U), Bank of America (BAC) and British American Tobacco Plc Ads (BATS).

Who are Hamilton Thorne's key executives?

Hamilton Thorne's management team includes the following people:

Ms. Meg Spencer, Co-Founder & Chairman
Mr. David B. Wolf, Pres, CEO & Director
Mr. Diarmaid H. Douglas-Hamilton, Co-Founder, Sr. VP of R&D, CTO, Corp. Sec. and Director
Mr. Michael W. Bruns, VP of Fin. & CFO (Age 62)
Dr. Fabian Sell, Chief Exec. Officer of Gynemed

What is Hamilton Thorne's stock symbol?

Hamilton Thorne trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HTL."

How do I buy shares of Hamilton Thorne?

Shares of HTL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Hamilton Thorne's stock price today?

One share of HTL stock can currently be purchased for approximately C$1.37.

How big of a company is Hamilton Thorne?

Hamilton Thorne has a market capitalization of C$189.32 million and generates C$38.12 million in revenue each year.

What is Hamilton Thorne's official website?

The official website for Hamilton Thorne is www.hamiltonthorne.com.

How can I contact Hamilton Thorne?

Hamilton Thorne's mailing address is 100 Cummings Ctr Ste 465e, BEVERLY, MA 01915-6143, United States. The company can be reached via phone at +1-978-9212050.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings